The PROGRESS Trial – Continued Access 2021-01-CAP
Research payments
$9,523,241
Through program year 2025, $9,523,241 in research payments was reported against The PROGRESS Trial – Continued Access 2021-01-CAP, across 383 payments, paid by Edwards Lifesciences Corporation.
- Paid by
- Edwards Lifesciences Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $7,142,403 | 277 |
| 2024 | Research | $2,380,838 | 106 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Philippe Genereux New York, NY Named on 22 payments
- Rahul Sakhuja Kingsport, TN Named on 19 payments
- Mark Pirwitz Austin, TX Named on 14 payments
- Ramzi Khalil Pittsburgh, PA Named on 11 payments
- Evelio Rodriguez Nashville, TN Named on 11 payments
- Sammy Elmariah San Francisco, CA Named on 10 payments
- Edwin Ho Bronx, NY Named on 10 payments
- John Forrest Hamden, CT Named on 9 payments
- Anthony Bavry Dallas, TX Named on 9 payments
- Amish Desai Portland, OR Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.